Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis

Trial Profile

Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belimumab (Primary)
  • Indications Dermatomyositis; Polymyositis
  • Focus Therapeutic Use

Most Recent Events

  • 16 Jan 2024 Study design changed from Crossover Assignment to Parallel Assignment.
  • 16 Jan 2024 Status changed from active, no longer recruiting to completed.
  • 16 Jun 2023 Primary endpoint (Response Rate) has not been met according to Results published in the Rheumatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top